• Kripto Paralar
  • Tahmin Piyasaları
  • Haberler
  • Ajansal İşlem
  • Yazılar
  • Ligler

Kripto Paraları Ara

Trend Kripto Paralar

CoinRithm

Şirket

Tüzel Kişilik
Bees-x Limited
Şirket Numarası
13308136
Kuruluş Yeri
England and Wales
Kayıtlı Ofis
Monmouth House, High Street, Watford, England, WD17 1LN

CoinRithm, Bees-x Limited tarafından işletilen bir bilgi ve araştırma hizmetidir. Düzenlenmiş faaliyetleri yürütmek üzere Financial Conduct Authority (FCA) tarafından yetkilendirilmemiştir ve bu sitedeki hiçbir içerik finansal tavsiye değildir.

Keşfet

Kripto ParalarTahmin PiyasalarıHaberlerYazılarAgent ArenaLigler

Özellikler

Kontrol PaneliTicaret SimülasyonuAjansal İşlemPortföyİzleme ListesiAyarlar

Şirket

HakkımızdaMetodolojiSınıflar içinKullanım ŞartlarıGizlilik PolitikasıÇerez PolitikasıFeragatname

Destek

Destekle İletişimSSSGeliştirici kitiMCP belgeleri

Sosyal Medya

X (Twitter)FacebookLinkedInTelegramInstagramTikTokYouTube
© 2026 CoinRithm. Tüm hakları saklıdır.
Google Play'de edininApp Store'dan İndirin
  • Ana Sayfa
  • PiyasalarTahmin Piyasaları
  • Haberler
  • Kontrol Paneli
  1. Tahmin Piyasaları
  2. China
  3. FDA decision: Ivonescimab by Summit Therapeutics (in 2026)
FDA decision: Ivonescimab by Summit Therapeutics (in 2026)

FDA decision: Ivonescimab by Summit Therapeutics (in 2026)

ChinaOne-OffHealth & Medicine6ay
KalshiKalshiKullanılabilirliği kontrol etKYC gerekli%2 ücret
Güncel ima edilen olasılık
Evet
Evet 0%
Piyasa kalitesi

24 / 100

Düşük kalite
24s Hacim

₺0

Likidite

₺0

Düşük likidite
Alis / Satis

54.0% / 62.0%

Spread

14.8%

Geniş spread
Piyasa verileri

1 dakika önce guncellendi

17 Haz 26 21:001 Oca 27 4:59

Trendler

Sonuç24sOlasılık
Evet
Evet
0%
Hayır
Hayır
100%

Seçilen sonuç

Yes0%

Kurallar

If the FDA's decision on Ivonescimab by Summit Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.

Kalshi
  • This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
  • Ivonescimab (also called AK112 or SMT112) is a bispecific antibody — think of it as a single engineered drug molecule that carries two different "hooks" instead of one, allowing it to grab and block two disease-promoting proteins at the same time.
  • It was developed by Akeso and is being commercialized outside China by Summit Therapeutics.
  • By simultaneously neutralizing both targets, ivonescimab is designed to slow cancer growth more effectively than drugs that block only one pathway at a time.

İlgili Piyasalar

Manifold Markets

Will China have more phase 3 drug trials than the United States in year X?

₺19,7 B
2026: 33%Manifold MarketsMANIFOLD MARKETS
Hantavirus pandemic in 2026?

Hantavirus pandemic in 2026?

₺2 Mn
Evet: 4%PolymarketPOLYMARKET
New pandemic in 2026?

New pandemic in 2026?

₺279,7 B
Evet: 11%PolymarketPOLYMARKET
Measles cases in U.S. by June 30?

Measles cases in U.S. by June 30?

₺116,8 B
2150: 41%PolymarketPOLYMARKET
Manifold Markets

How many movies will gross >$1 billion in 2026?

₺67,3 B
0-3: 5.7%Manifold MarketsMANIFOLD MARKETS
Manifold Markets

Testosterone unscheduled/rescheduled more permissively in US by end of 2028?

₺53,3 B
Evet: 22.2%Manifold MarketsMANIFOLD MARKETS

Bu konularda aktif

BitcoinBTC$64,459.02-1.96%EthereumETH$1,749.02-2.59%SolanaSOL$72.02-2.37%DogecoinDOGE$0.086-1.52%XRPXRP$1.19-2.66%BNBBNB$601.09-0.82%

İlgili Haberler

Chinese Man Gets 10+ Years for Stealing 107 BTC Using Memorized KeyBlockchain.NewsPentagon adds Alibaba, Baidu and BYD to China’s military-linked list Crypto NewsNvidia’s CEO declines Senate testimony on China’s AI chip businessCrypto NewsChina warns developers over overseas AI relay servicesCrypto NewsChina court treats Bitcoin as property in 107 BTC theft caseCrypto NewsChinese court treats Bitcoin as property in 107 BTC memory theft caseCointelegraph

Kurallar

If the FDA's decision on Ivonescimab by Summit Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.

Kalshi
  • This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
  • Ivonescimab (also called AK112 or SMT112) is a bispecific antibody — think of it as a single engineered drug molecule that carries two different "hooks" instead of one, allowing it to grab and block two disease-promoting proteins at the same time.
  • It was developed by Akeso and is being commercialized outside China by Summit Therapeutics.
  • By simultaneously neutralizing both targets, ivonescimab is designed to slow cancer growth more effectively than drugs that block only one pathway at a time.